

Index

- abdomen
 in pelvic organ prolapse, 236
 UI examination, 224
- abdominal aortic aneurysm, 499
- abdominal pain
 acute, 434
 in adenomyosis, 440
 in adhesive disease, 441
 adnexal masses in, 440–1
 chronic, 434
 connective tissue and, 441
 early pregnancy and, 438–9
 in endometriosis, 439
 extra-abdominal etiology, 441
 female reproductive tract
 and, 438
 gastrointestinal causes of, 436–7
 in geriatric population, 502
 hypogastric, 435
 left iliac, 435
 location, 434
 migratory, 434
 musculoskeletal system and, 441
 organ system approach to, 436
 in ovarian torsion, 440
 pelvic inflammatory disease in, 439
 physiology of, 433
 related symptoms, 434
 renal system and, 437–8
 right hypochondriac, 436
 right iliac, 436
 types of, 433
 uterine leiomyoma, 440
- abdominal pregnancy, 55
- ABIM. *See* American Board of Internal Medicine
- abnormal artery embolization
 MRI for, 179
 UAE, 179–81
- abnormal uterine bleeding, 168
 anticoagulants and, 171
 causes, 172
 classification, 168
 COEIN, 170–1
 definition, 168
 diagnostic tests, 172
 endometrial ablation, 178
 endometrial causes, 171
 histologic assessment, 174
 hysterectomy, 178–9
 iatrogenic causes, 171
 laboratory analysis, 172
 medical management, 174–7
 medications causing, 171
 myolysis, 178
 myomectomy, 178
 PALM, 169–70
 patent history, 171–2
 physical exam, 171–2
 radiological procedures, 179
 surgical management, 177–8
 symptoms, 172
 terminology, 168–9
 uterine assessment, 172–4
- abortion
 adverse events, 143
 counseling, 140
 informed consent, 140
 medical, 141
 candidates for, 142
 complications, 143–4
 evidence-based, 142
 FDA-approved, 142
 follow-up, 143
 infections, 143
 medications, 142
 pain management, 146–7
 patient expectations, 143
 regimens, 142
 medical evaluation, 141
 missed
 diagnosis, 121–3
 treatment, 121–3
 pain management, 146
 patient education, 140
 services
 accessibility of, 139
 costs, 140
 distance to, 140
 harassment and, 140
 legal concerns, 140
 surgical, 141
 antibiotic management, 147–8
 appropriate office candidate, 144
 cannula in, 144
 cervical lacerations and, 146
 cervical preparation, 144
 complications, 145–6
 dilators in, 144
 equipment, 144
 first trimester, 144
 general anesthesia, 147
 hematometra and, 146
 hemorrhage, 146
 incomplete, 146
 medical abortion and, 141
 pain management, 147
 paracervical block, 147
 premedications, 147
 procedure, 144–5
 sedation, 147
 uterine perforation in, 146
 vasovagal episodes, 146
 threatened, 120–1
 ABPM. *See* ambulatory blood pressure monitoring
 absorbent products, 229
 acamprosate, 485
 Acetic acid, 76
 acidosis, 99
 acne
 in hyperandrogenism, 324
 physical exam, 324
 treatment, 329
 ACOG. *See* American Congress of Obstetrics and Gynecology
 acquired hypogonadotropic hypogonadism, 354
 ACS NSQIP. *See* American College of Surgeons National Surgical Quality Improvement Program
 ACTH. *See* adrenocorticotrophic hormone
 activated partial thromboplastin time (aPTT), 65
 Activin, 312
 acupuncture
 for endometriosis, 280
 smoking cessation and, 427
 acute abdominal pain, 434
 acute asthma
 initial management, 95
 investigations, 95
 office emergencies, 94–5
 presentation, 95
 acute coronary syndrome
 initial management, 93–4
 investigations, 94
 office emergencies, 92–3
 presentation, 94

Index

- acute lymphocytic anemia, 27
 acute myelogenous anemia, 27
 acute pelvic pain
 approach to, 198
 clinical examination, 199–200
 differential diagnosis, 199
 history, 199
 imaging, 200
 invasive diagnosis, 200
 investigations, 200
 medical treatment, 200
 prevention, 201
 scope, 198
 sexual history and, 199
 surgical treatment, 200–1
 ultrasound, 200
 acyclovir, 188
 ADA. *See* American Disabilities Act
 Addison's disease, 356
 causes, 356
 presentation, 356
 adenocarcinoma in situ (AIS), 80
 diagnosis, 87
 excisional procedure, 87
 adenoma, 332
 lactating, 372
 adenomatous polyposis coli (APC), 45
 adenomyosis, 169
 abdominal pain in, 440
 ADH. *See* antidiuretic hormone
 adhesive disease, 441
 adnexa, 124
 adnexal mass, 56–7, 218
 in abdominal pain, 440–1
 nonovarian, 215
 preoperative evaluation, 63
 adnexal torsion, 214
 adolescents
 alcohol use disorder in, 486
 disability, 515
 intimate partner violence in, 520
 pregnancy and, 490
 substance abuse disorders in, 489
 adoptive nursing, 35
 adrenal disorders, 327
 adrenaline, 91
 adrenarche, 357
 adrenocorticotrophic hormone (ACTH), 322, 357
 adrenoreceptor agonists, 230
 AES. *See* Androgen Excess Society
 AFSF. *See* atypical femoral shaft fractures
 AGC. *See* atypical glandular cells
 age
 in patient history, 367
 sexual dysfunction and, 268
 agency, 536
 Agency for Healthcare Research and Quality (AHRQ), 26, 425
 air emboli, 98
 AIS. *See* adenocarcinoma in situ;
 androgen insensitivity syndrome
 AIUM. *See* American Institute of
 Ultrasound Medicine
 albuterol, 95
 alcohol
 annual examination, 11
 breastfeeding and, 30
 osteoporosis and, 476
 preconception counseling, 111
 subfertility and, 286
 alcohol use disorder (AUD), 483–4
 in adolescents, 486
 brief intervention, 485–6
 pharmacotherapy, 485
 prevention, 486–7
 referrals for treatment, 486
 screening, 483–4
 Aldactone, 318
 ALLOW model, 266–7
 alopecia
 in hyperandrogenism, 324
 physical exam, 324
 alpha thalassemia, 109–10
 Alzheimer's disease, 499
 ambulatory blood pressure monitoring (ABPM), 446
 amenorrhea, 160, 353
 androgen insensitivity syndrome, 164
 anorexia nervosa and, 353–4
 Asherman syndrome, 164–5
 cervical atresia, 163
 cervical stenosis, 164
 diagnosis, 160
 evaluation, 165, 354
 genital outflow tract disorders and, 162–3
 gonadal dysgenesis and, 162
 hypothalamic, 160–1, 353–4
 imaging, 166
 imperforate hymen, 163
 laboratory testing, 165–6
 lactational, 26–8
 Mullerian agenesis, 163–4
 ovarian disorders and, 161–2
 patient history, 165
 physical exam, 165
 pituitary causes, 161
 premature ovarian failure, 162
 psychological consequences of, 166
 transverse vaginal septum, 163
 treatment, 160, 161
 Turner syndrome and, 162
 ultrasound, 166
 uterine tract disorders and, 162–3
 American Board of Internal Medicine (ABIM), 65
 American College of Surgeons
 National Surgical Quality Improvement Program (ACS NSQIP), 68
 American Congress of Obstetrics and Gynecology (ACOG), 24, 65, 82, 125–6
 American Disabilities Act (ADA), 508–9
 American Heart Association
 advanced life support algorithm, 94
 basic life support algorithm, 93
 American Institute of Ultrasound Medicine (AIUM), 49
 practice guidelines, 50
 American Society for Colposcopy and Cervical Pathology (ASCCP), 80
 American Society of Reproductive Medicine (ASRM), 55–6
 AMH. *See* anti-müllerian hormone
 aminocaproic acid, 157
 amiodarone, 91
 amlodipine, 448–9
 amoxicillin-clavulanate, 384
 anal wink, 236
 analgesia, 204
 anaphylaxis
 chlorpheniramine for, 97–8
 hydrocortisone for, 97–8
 initial management, 97–8
 office emergencies, 97
 presentation, 97
 androgen, 156
 PCOS and, 312
 production of, 322
 Androgen Excess Society (AES), 315–16
 androgen insensitivity syndrome (AIS), 365
 amenorrhea, 164
 androgen producing tumors, 172
 androgen receptor
 antagonist, 328
 defects, 358
 anemia
 acute lymphocytic, 27
 acute myelogenous, 27
 iron deficiency, 113
 preconception counseling, 107
 aneuploidy
 noninvasive prenatal testing, 133
 screening, 133
 ultrasound for, 133–4
 annual examination
 alcohol abuse, 11
 Basic well-woman examination
 patient history, 1
 physical examination, 1
 bone health, 3–4

Index

- BRCA 1/2 mutation and, 2
 breast self-awareness and, 2
 BSE and, 2
 cancer screening, 2
 cervical cancer, 2–3
 clinical breast examination, 2
 colorectal cancer, 3
 depression, 11–12
 diabetes, 12
 enhanced screenings, 2
 exercise, 12–13
 fall prevention, 11
 family planning, 7–8
 FRAX, 4
 heart and vascular health, 4–7
 hypertension, 4–6
 illicit drug use, 11
 immunizations and, 8–9
 infection screening, 9–11
 intimate partner violence, 11
 lung cancer, 3
 mammography, 2
 nutrition, 12–13
 obesity, 12–14
 osteoporosis screening, 4
 ovarian cancer, 3
 pelvic examination, 2
 preventive health care, 1
 safe driving practice, 11
 smoking, 11
 stroke prevention and, 7–8
 anorexia nervosa, 405–6
 amenorrhea and, 353–4
 cardiovascular changes in, 409
 characteristics, 405–6
 dermatologic changes in, 408–9
 endocrine system in, 409
 epidemiology, 407–8
 gastrointestinal changes in, 409
 management, 410–11
 medical complications, 408
 neurologic changes in, 409
 pathogenesis, 408
 prognosis, 410–11
 renal changes in, 410
 reproductive lifecycle and, 409–10
 screening tools, 410
 signs and symptoms, 406
 antenatal testing, 135
 antepartum testing, 135
 antibiotics
 surgical abortion, 147–8
 for UTI, 384
 anticoagulants, 171
 antidepressants
 atypical, 400
 smoking cessation and, 427–9
 for UI, 230
 antidiuretic hormone (ADH), 355
 anti-estrogens, 298–9
 antifibrinolytics, 157, 176
 antihypertensives
 selected agents, 448–9
 side effects, 449
 anti-müllerian hormone
 (AMH), 292
 antimuscarinics, 230–1
 antiphospholipid antibodies, 113
 antiresorptive medications, 472–4
 antiretroviral therapy (ART), 86–8, 194
 dosing, 188
 anxiety, 268
 anxiolytics, 427–9
 APC. *See* adenomatous polyposis coli
 appendicitis, 363
 aPTT. *See* activated partial thrombo-
 plastin time
 arcuate uterus, 51, 361
 aromatase inhibitors
 complications, 300
 for endometriosis, 280
 for infertility, 300
 mechanism of action, 300
 outcome of treatment, 300
 arousal, 263
 combined sexual arousal disorder,
 264
 disorders, 271
 genital arousal disorder, 264
 persistent sexual arousal disorder,
 264
 subjective sexual arousal disorder,
 264
 ART. *See* antiretroviral therapy
 ASCCP. *See* American Society for
 Colposcopy and Cervical
 Pathology
 ASC-H. *See* atypical squamous cells
 ascites, 57
 ASCUS. *See* atypical squamous cells of
 undermined significance
 Asherman syndrome, 164–5
 Ashkenazi Jewish panel, 113
 aspirin, 91, 171
 ASRM. *See* American Society of
 Reproductive Medicine
 assisted living devices, 511
 assisted reproductive technologies, 277
 in endometriosis, 281
 medical pretreatment, 282
 asthenospermia, 287
 asthma, 27
 preconception counseling, 107
 asymptomatic bacteruria, 132
 asymptomatic carotid artery
 stenosis, 499
 atopic dermatitis, 27
 atropine, 92
 atypical antidepressants, 400
 atypical femoral shaft fractures
 (AFSF), 477
 atypical glandular cells (AGC), 80
 in CIN, 86
 initial workup, 87
 subsequent management, 87
 atypical squamous cells (ASC-H), 80, 87
 in women aged 21–4, 84
 atypical squamous cells of undermined
 significance (ASCUS), 80, 85
 in women aged 21–4, 84
 AUD. *See* alcohol use disorder
 autonomic dysreflexia, 512–13
 autonomic stress syndrome, 512–13
 autonomy, 536
 aversion therapy, 429
 azilsartan, 448–9
 azithromycin, 185, 190
 BA. *See* behavioral activation
 bacterial vaginosis, 68–9, 239, 247–9
 diagnosis of, 249
 risk factors, 247–9
 symptoms, 249
 treatment, 251
 bacteriuria, 9, 380
 Baden-Walker system, 63, 237
 bariatric surgery, 419
 barrier contraception, 19–23
 BAS. *See* bile acid sequestrants
 Basic well-woman examination
 annual examination, 1
 patient history, 1
 physical examination, 1
 beak sign, 121
 Beauchamp, Tom, 535
 behavioral activation (BA), 401
 behavioral therapy
 for marijuana abuse, 489
 for obesity, 417
 opiate abuse, 488
 for stimulant abuse, 488
 behavioural therapies, 228
 benazepril, 448–9
 benevolence, 535–6
 benign pituitary adenomas, 161
 benzodiazepines, 95–6, 111
 beta-3-adrenoceptor agonist, 231
 beta human chorionic gonadotropin,
 119
 discriminatory level of, 124
 beta thalassemia, 109–10
 Bethesda system, 80, 83
 bichloroacetic acid, 192
 bicornate uterus, 51, 361
 bilateral oophorectomy, 269
 bilateral salpingo-oophorectomy
 (BSO), 42–3
 for BRCA1, 43
 for BRCA2, 43

Index

- bilateral (BSO) (cont.)
 for Lynch syndrome, 45
 for ovarian cancer, 43
 bile acid sequestrants (BAS), 464
 bimanual exam, 269
 binge drinking, 483
 binge-eating disorder, 407
 comorbid disorders, 407
 pathogenesis, 408
 bioethics. *See also* ethical issues
 autonomy, 536
 benevolence and, 535–6
 case studies, 540–2
 communication model, 540
 competing obligations in, 536–8
 deliberative model, 538–9
 informative model, 539
 interpretive model, 539
 justice, 536
 non-maleficence, 535–6
 paternalistic model, 538–9
 patient–physician communication, 538
 pillars of, 535
 biofeedback, 227
 biopsy, 85
 bisphosphonates, 472–3
 Black Box warnings, 20
 bladder diary, 225
 bladder training, 228
 blighted ovum, 54
 diagnosis, 121–3
 treatment, 121–3
 ultrasound, 121
 blood loss preparation, 69–70
 blood pressure management, 5
 BMD. *See* bone mineral density
 body mass index (BMI), 14
 bone density, 346
 bone health, 3–4
 bone mineral density (BMD), 4
 interpretation of, 4
 bone turnover, 471
 botulinum toxin, 208
 bowel symptoms, 223
 bradycardia, 409
 BRCA1, 39, 367
 annual examination and, 2
 BSO for, 43
 family history, 40
 future research, 43
 genetic counseling, 40, 41
 lifestyle modifications, 43
 limitations of testing, 43
 oral contraceptives and, 42
 risk-reducing surgery, 42–3
 screening, 39–40
 result interpretation, 41
 surveillance of carriers, 41–2
 BRCA2, 39, 367
 annual examination and, 2
 BSO for, 43
 family history, 40
 future research, 43
 genetic counseling, 40, 41
 lifestyle modifications, 43
 limitations of testing, 43
 oral contraceptives and, 42
 risk-reducing surgery, 42–3
 screening, 39–40
 result interpretation, 41
 surveillance of carriers, 41–2
 BRCAPRO, 40
 breast abscess, 33
 breast cancer, 27
 chemoprevention, 42
 in geriatric population, 501
 breast complaints
 CNB and, 370
 FNAC and, 370
 mammography and, 369
 MRI and, 370
 patient history, 367–8
 physical examination, 368
 ultrasound and, 369–70
 breast cysts, 372
 breast evaluation, 33
 breast masses
 breastfeeding and, 33
 clinically benign, 370–1
 clinically suspicious, 371
 evaluation, 370
 palpable mass, 370–1
 scope of problems in, 370
 indeterminate, 371
 palpable, management of, 371
 breast self-awareness, 2
 breast self-examination (BSE), 2
 breastfeeding, 22–3. *See also* lactation
 adoptive nursing and, 35
 alcohol and, 30
 barriers to, 29–30
 benefits of, 26–8
 bloody nipple discharge and, 33
 breast abscess and, 33
 breast masses and, 33
 cessation of, 28
 challenges, 32–3
 contraindications, 30
 custody and, 35
 in developed countries, 26–8
 disasters and, 35
 drug abuse and, 30
 engorgement and, 32
 exam, 31
 extended, 34
 fish lips in, 32
 goals, 26
 inadequate glandular tissue, 31
 infant outcomes, 28
 infant separation and, 34
 latch, 31–2
 long-term issues, 34
 management, 30–1
 peripartum support, 31
 postpartum, 31
 preconception, 30
 prenatal, 31
 mastitis and, 32–3
 maternal illness and, 34
 maternal medications and, 30
 maternal nutrition and, 34
 maternal outcomes, 26–8
 milk fistula and, 33
 multiples, 34
 nipple pain and, 32
 nipple piercings and, 31
 pacifiers and, 31–2
 patient approach
 business case for, 29
 education, 29
 family and social support, 29–30
 office in, 29–30
 provider education, 29
 plugged ducts and, 32
 premature infants and, 35
 pumping and, 34–5
 rates, 26
 recommendations, 26
 relactation, 35
 school and, 34
 smoking and, 30
 suboptimal, 28
 successful, 27
 tandem, 34
 techniques, 31–2
 technology, 34–5
 twins, 34
 work and, 34
 bromocriptine, 334, 377
 pregnancy and, 336
 bronchodilators, 95
 BSE. *See* breast self-examination
 BSO. *See* bilateral salpingo-oophorectomy
 bulbocavernosus reflex, 236
 bulimia nervosa, 406–7
 cardiovascular changes in, 409
 characteristics, 407
 core features, 406
 dermatologic changes in, 408–9
 endocrine system in, 409
 epidemiology, 407–8
 gastrointestinal changes in, 409
 management, 410–11
 medical complications, 408
 pathogenesis, 408
 prognosis, 410–11
 renal changes in, 410
 reproductive lifecycle and, 409–10

- screening tools, 410
 severity of, 406–7
 bupivacaine, 99
 buprenorphine, 487–8
 bupropion, 111, 400, 428
 buspirone, 391
 butoconazole, 246–8
 butorphanol, 31
- CA125, 219
 cabergoline, 334–5
 pregnancy and, 336
 cachexia, 496
 caffeine, 475–6
 CAH. *See* congenital adrenal hyperplasia
 CAIS. *See* complete androgen insensitivity syndrome
 calcitonin, 474
 calcium, 110, 391–2
 osteoporosis and, 474–5
 recommendations, 4
 candesartan, 448–9
Candida albicans, 157, 243, 246–7
Candida glabrata, 157
 cannula, 144
 captopril, 448–9
 carbon dioxide, 294
 cardiac arrest
 initial management, 92
 office emergencies, 92
 presentation, 92
 cardiac evaluation algorithm, 67
 cardiovascular disease
 in geriatric populations, 498
 hormonal contraception and, 454–5
 hormone therapy and, 454–5
 lifestyle management, 458–61
 menopause, 346
 OCP and, 454–5
 preconception counseling, 108
 scope of problems, 453
 screening, 453–4
 cardiovascular system, 236
 Carnett's test, 441
 catheters, 229
 indwelling, 386
 for UI, 229
 CBT. *See* cognitive behavioral therapy
 CDC. *See* Centers for Disease Control and Prevention
 cefaclor, 384
 cefdinir, 384
 cefixime, 185
 cefoxitin, 186
 cefpodoxime-proxetil, 384
 ceftriaxone, 190
 Centers for Disease Control and Prevention (CDC), 82
 central hypogonadism, 353
- cephalosporins, 185
 cervical atresia, 163
 cervical cancer
 annual examination, 2–3
 in geriatric population, 500–1
 prenatal screening, 132
 substance abuse disorders and, 489–90
 cervical intraepithelial neoplasia (CIN), 80–1
 abnormal cytology results, 85
 in adolescents, 83–4
 atypical glandular cells, 86
 biopsy, 85
 colposcopy, 83
 cytology, 82–3
 negative but EC/TZ absent, 85
 findings of no lesion, 85
 high grade lesions, 86
 HIV and, 86–8
 incidence of, 81
 LEEP for, 88
 lesser abnormalities, 80
 management, 83
 mortality from, 81
 natural history of, 81–2
 prevention of, 82
 risk factors, 82
 screening for, 82–3
 suboptimal cytology results, 84–5
 treatment, 88
 in women aged 21–4, 84
 in young women, 86
 cervical lacerations, 146
 cervical lengths, 134
 cervical pregnancy, 55
 cervical preparation, 144
 cervical stenosis, 164
 cesarean section, 52
 Chadwick's sign, 132–3
 chancroid, 190
 chemoprevention
 breast cancer, 42
 oral contraceptives for, 42
 childbearing potential, 450
 childhood obesity, 27
 childhood sexual abuse, 269
 Childress, James, 535
 chlamydia, 184, 243, 286
 epidemiology, 184
 pathophysiology, 184–5
 screening, 9, 185
 treatment, 185
 chlorpheniramine, 91
 for anaphylaxis, 97–8
 chlorthalidone, 448–9
 chorionic sac, 52–3
 chorionic villi, 53, 133
 chronic abdominal pain, 434
 chronic pelvic pain
- analgesia for, 204
 approach to, 201–2
 causes of, 201
 clinical examination, 203
 common conditions of, 202
 history, 202–3
 hormonal based treatment, 204–5
 invasive diagnosis, 203
 investigations, 203
 medical treatment of, 205
 neuromodulation for, 205
 neuropathic pain, 205
 physiotherapy, 205
 prevention, 205
 psychological therapy, 205
 red flag symptoms, 202
 scope of problem, 201
 surgery, 205
 treatment, 203–4
 CIN. *See* cervical intraepithelial neoplasia
 ciprofloxacin, 190, 384, 385
 clindamycin, 73–4, 246–8, 251
 clinical breast examination, 368–9
 annual examination, 2
 inspection, 368
 palpation, 368–9
 clinically benign breast masses, 370–1
 clinically suspicious breast masses, 371
 clitoromegaly, 325
 clomiphene, 318
 clomiphene citrate
 complications, 299
 mechanism of action, 298
 outcome of treatment, 299
 plan of action, 298–9
 clonidine, 344, 488
 clopidogrel, 91
 clotrimazole, 246–8
 CMV. *See* cytomegalovirus
 CNB. *See* core needle biopsy
 CO₂ detector, 90
 coagulopathy, 172
 COC. *See* combined oral contraceptives
 cocaine, 488
 Cochrane review, 122–3
 cognitive behavioral therapy (CBT), 400–1
 cognitive dysfunction, 345
 Collaborative Review of Sterilization (CREST), 18
 colon cancer, 501
 colorectal cancer, 44–5. *See also* Lynch syndrome
 annual examination, 3
 general population screening, 3
 colostrum, 28–9
 colpocleisis, 240

Index

- colposcopy, 83
 combined oral contraceptives (COC), 328
 combined sexual arousal disorder, 264
 complete androgen insensitivity syndrome (CAIS), 363–4
 complete blood count, 65
 prenatal care, 132
 complex ovarian cyst, 56
 computed tomography (CT)
 pelvic masses, 212–13
 in uterine leiomyoma, 258
 condom, 19, 187–8
 condyloma lata, 189
 condylomata acuminatum, 189
 confidentiality, 152
 congenital adrenal hyperplasia (CAH), 172, 323, 364
 adult onset, 357–8
 hyperandrogenism and, 327
 puberty and, 357–8
 congenital hypogonadotropic hypogonadism, 353–4
 congenital malformation, 131
 connective tissue, 441
 contraception. *See also* oral contraceptive pill
 barrier, 19–23
 contraceptive ring, 20
 contraceptive sponge, 19
 counseling, 8, 148
 disability and, 513–14
 effectiveness, 17–18
 emergency, 21
 ending, 24
 estrogen-progestin, 176
 history of, 17
 HIV and, 18
 hormonal, 19–23
 cardiovascular disease and, 454–5
 for endometriosis, 279
 implants, 22–3
 initiation, 148
 maternal death and, 17
 method choice, 18
 obesity and, 419–21
 reversible, 19–23
 sexual dysfunction and, 268–9
 STDs and, 18
 substance abuse disorders and, 489
 Contraceptive CHOICE study, 139
 copper IUD, 21
 core needle biopsy (CNB), 370
 coronary heart disease
 in geriatric population, 498–9
 risk factors, 7
 corticotroph, 161
 cortisol, 356
 co-test, 80
 cotton swab test, 269
 Couch model, 40
 cough stress test, 224
 Coumadin, 171
 CRAFFT screening, 486
 CREST. *See* Collaborative Review of Sterilization
 crown rump length (CRL), 53
 CT. *See* computed tomography
 cul de sac, 120
 Cushing's disease, 356
 diagnosis of, 356
 hyperandrogenism and, 327–8
 custody, 35
 cyproterone acetate, 328
 cystadenofibromas, 56
 cystadenomas
 mucinous, 216–17
 serous, 58, 216–17
 cystic corpus lutea, 58
 cystic fibrosis, 109–10
 carrier testing, 113
 cystitis, 383–4
 cytomegalovirus (CMV), 111–12
 danazol, 377, 390
 for endometriosis, 280
 DASH. *See* Dietary Approaches to Stop Hypertension
 deep dyspareunia, 208
 defecatory dysfunction, 235–6
 dehydroepiandrosterone (DHEA), 322
 delayed puberty, 353–4
 laboratory analysis, 156
 PAG and, 151–2, 153
 physical exam, 154
 treatment, 157–8
 deliberative model, 538–9
 delivery timing, 135–6
 denosumab, 473–4
 densitometric diagnosis, 469
 dental health
 in geriatric population, 498
 preconception counseling, 111
 Denver Developmental Screen, 112
 depilation, 329
 depression, 394
 annual examination, 11–12
 atypical antidepressants for, 400
 cognitive behavioral therapy for, 400–1
 ECT for, 401
 exercise for, 401
 financial impact of, 394
 interpersonal therapy for, 401
 laboratory assessment, 396–7
 MSE in, 396
 PCOS and, 316
 perimenopause and, 402
 pharmacological treatment, 399
 physical exam and, 395–6
 physician and legal responsibility, 402
 postpartum, 26–8, 30, 402
 pregnancy and, 402
 psychotherapy for, 400–1
 reproductive lifecycle and, 401
 scope of, 394
 screening, 394–5
 sexual dysfunction and, 268
 SNRIs for, 399
 social history and, 395
 SSRIs for, 399
 suicide and, 395
 symptoms, 11–12
 TCAs for, 399–400
 treatment, 398–9
 dermoid cysts, 58, 215–17
 desire, 263
 desquamative inflammatory vaginitis (DIV), 250
 diagnosis, 250
 etiology, 250
 symptoms, 250
 treatment, 250
 Detrusor Hyperreflexia, 221
 developed countries, 26–8
 dexamethasone, 95
 DHA. *See* docosahexaenoic acid
 DHEA. *See* dehydroepiandrosterone
 diabetes insipidus (DI), 354–6
 causes of, 355
 diagnosis, 355
 management, 356
 nephrogenic, 356
 pregnancy and, 356
 symptoms, 355
 diabetes mellitus
 annual examination, 12
 PCOS and, 316
 preconception counseling and, 105–6
 risk factors for, 115
 type 2, 27
 UTIs and, 385–6
 diaphragm (contraception), 19
 diarrhea, 27
 diazepam, 95–6
 Dietary Approaches to Stop Hypertension (DASH), 458–60
 dilators
 in surgical abortion, 144
 vaginal, 362
 diltiazem, 448–9
 disability, 507
 abuse and, 513
 adolescents, 515
 assisted living devices, 511
 autonomic dysreflexia and, 512–13
 autonomic stress syndrome, 512–13
 auxiliary aids, 510
 contraception and, 513–14

- gynecologic care in, 509–12
 infertility and, 514–15
 intimate partner violence, 520–1
 scope of problems, 507–8
 sexual dysfunction and, 513
 sexuality and, 513
 sterilization and, 514
 violence and, 513
 disasters, 35
 Disorders of Sexual Development (DSD), 360, 363–4, 365
 distal radius fractures, 468
 disulfiram, 485
 DIV. *See* desquamative inflammatory vaginitis
 diverticular disorders, 437
 diverticulitis, 437
 diverticulosis, 437
 docosahexaenoic acid (DHA), 110
 domestic violence. *See* intimate partner violence
 dopamine agonists, 337
 Down's syndrome, 133
 identification of, 133
 doxycycline, 73–4, 185, 186
 drug abuse
 breastfeeding and, 30
 preconception counseling, 111
 DSD. *See* Disorders of Sexual Development
 dual-energy x-ray absorptiometry (DXA), 4
 DUB. *See* dysfunctional uterine bleeding
 ductography, 373
 duloxetine, 205, 230
 DXA. *See* dual-energy x-ray absorptiometry
 dysesthesia, 433
 dysfunctional uterine bleeding (DUB), 168
 dyslipidemia, 319
 in geriatric populations, 498
 dysmenorrhea, 286, 361–2
 dyspareunia, 206, 264, 270, 345
 clinical examination, 207
 deep, 208
 investigations, 207
 patient approach, 206
 patient history, 206–7
 superficial, 207–8
 treatment, 207
 dysuria, 382
 early delivery, 136
 early embryonic size (EES), 53
 early pregnancy, 438–9
 symptomatic, 125
 eating disorders, 405
 cardiovascular changes in, 409
 dermatologic changes in, 408–9
 endocrine system in, 409
 epidemiology, 407–8
 management, 410–11
 medical complications, 408
 neurologic changes in, 409
 pathogenesis, 408
 prevalence of, 405
 prognosis, 410–11
 renal changes in, 410
 reproductive lifecycle and, 409–10
 screening for, 405, 410
 EC. *See* emergency contraception
 ECT. *See* electroconvulsive therapy
 ectopic pregnancy, 53, 54–5, 118
 diagnosis, 123–6
 gestational age assessment and, 141–2
 pelvic masses and, 213–14
 risk factors, 119
 treatment, 123–6
 EC/TZ. *See* endocervical/transformation zone
 EDCs. *See* endocrine disrupting chemicals
 EDD. *See* estimate a date of delivery
 education
 patient, 29
 provider, 29
 EES. *See* early embryonic size
 eflornithine hydrochloride, 328
 Electric Vacuum Aspirator (EVA), 144, 145
 electrical stimulation, 228
 electroconvulsive therapy (ECT), 401
 electronic cigarettes, 429
 elliptical incision biopsy, 77
 embolic complications
 initial management, 99
 initial presentation, 98–9
 investigations, 99
 office emergencies, 98
 embolization versus hysterectomy (EMMY), 181
 embryonic period, 53
 embryonic reabsorption, 54
 emergency contraception (EC), 21
 emergency trolley, 91
 contents, 91
 EMMY. *See* embolization versus hysterectomy
 emotional considerations, preoperative evaluation, 64–5
 enalapril, 448–9
 end of life decision making, 503–4
 endocervical/transformation zone (EC/TZ), 80
 absence, 85
 endocrine disrupting chemicals (EDCs), 112
 endometrial ablation
 abnormal uterine bleeding, 178
 office procedures, 74
 endometrial biomarkers, 279
 endometrial cancer, 170
 endometrial cavity, 121
 endometrial hyperplasia, 170, 317
 endometrial polyp, 52, 169
 endometrial sampling, 174
 endometriomas, 56, 216, 274–5
 surgical removal, 281–2
 treatment, 281
 endometriosis, 274
 abdominal pain in, 439
 acupuncture for, 280
 adjuvant therapy, 280–1
 aromatase inhibitors for, 280
 ART in, 281
 clinical examination, 276
 danazol for, 280
 diagnosis, 275–6
 differential diagnosis, 276
 endometrial biomarkers, 279
 estrogen in, 275
 gestrinone for, 280
 GnRH agonists for, 279–80
 hormonal contraception for, 279
 hysterectomy for, 280
 infertility and
 ART pretreatment, 282
 surgical treatment, 281–2
 treatment, 281
 laparoscopic diagnosis, 277
 laparoscopic uterosacral nerve ablation for, 280
 medical technologies for diagnosis, 276–7
 medical treatment, 279, 281
 MRI in, 278
 NSAIDs for, 279
 pain assessment, 276
 pain in, 275
 pain treatment, 279
 pathogenesis, 274
 pathophysiology, 274–5
 peripheral biomarkers, 278
 presacral neurectomy for, 280
 progestagens for, 279
 progesterone in, 275
 risk factors, 275
 surgical therapy, 280
 symptoms, 276
 ultrasound examination, 277–8
 endometrium, 58–9
 fertility scan, 289–91
 receptivity, 289–91
 engorgement, 28
 breastfeeding and, 32

Index

- Enovid, 17
Enterobius vermicularis, 157
 environmental exposures, 113
 contaminants, 112
 preconception counseling, 111–12
 ephedrine, 230
 epilation, 329
 epilepsy, 106–7
 epinephrine, 92
 eprosartan, 448–9
 erythromycin, 190
 ESHE. *See* European Society of Human Reproduction and Embryology
 Essure, 18, 23–4
 estimate a date of delivery (EDD), 130
 estradiol, 311–12, 345
 estrogen, 20, 311–12
 in endometriosis, 275
 for osteoporosis, 474
 for UI, 230
 for vasomotor symptoms, 344
 estrogen-progestin contraceptives, 176
 ethical issues, 535. *See also* bioethics
 substance abuse disorders and, 491
 ethnicity
 hyperandrogenism and, 323–4
 obesity and, 414
 preconception counseling, 109–10
 etonogestrel, 20
 European Society of Human Reproduction and Embryology (ESHRE), 55–6
 EVA. *See* Electric Vacuum Aspirator
 evening primrose oil, 377
 exercise
 annual examination, 12–13
 for depression, 401
 geriatric population, 496
 guidelines, 12–13
 for infertility, 298
 osteoporosis and, 476
 preconception counseling and, 111
 pregnancy and, 111
 smoking cessation and, 427
 extended breastfeeding, 34
 fall prevention
 annual examination, 11
 in osteoporosis, 470–1
 fallopian tube
 cancer, 55
 torsion, 55
 Falope Ring, 23
 famciclovir, 188
 familial adenomatous polyposis (FAP), 3, 45
 familial hypercholesterolemia (FHC), 456–8
 age-specific lipid levels, 456
 at-risk lipid levels in, 456
 genetic mutations, 456
 lifestyle modifications in, 461
 pharmacotherapy, 464
 treatment guidelines, 463
 family history
 BRCA1, 40
 BRCA2, 40
 hyperandrogenism and, 323–4
 preconception counseling, 109–10
 family planning
 annual examination, 7–8
 clinics, 139
 family support, 29–30
 FAP. *See* familial adenomatous polyposis
 FASD. *See* fetal alcohol spectrum disorder
 feedback inhibitor of lactation (FIL), 28–9
 felodipine, 448–9
 female reproductive tract, 438
 anomalies, 360
 communication and, 364–5
 Female Sexual Distress Scale (FSDS), 269
 Female Sexual Function Index (FSFI), 269
 female sexual response, 263–5
 arousal in, 263
 desire in, 263
 plateau, 263
 resolution, 263–4
 fertility scan, 288
 endometrium, 289–91
 hysteroscopy, outpatient, 293–4
 ovarian reserve assessment, 291–2
 tubal patency assessment, 292–3
 uterus, 289
 fetal alcohol spectrum disorder (FASD), 490
 fetal anatomic survey, 133–4
 fetal demise, 130
 FHC. *See* familial hypercholesterolemia
 fibroadenomas, 371–2
 natural history, 371–2
 fibroids, 53, 211. *See also* uterine leiomyoma
 classification of, 256–7
 large benign, 255
 pedunculated, 256–7
 fibromas, 57–8
 FIGO, 169
 FIL. *See* feedback inhibitor of lactation
 Filshie Clip, 23
 finasteride, 318, 328
 fine needle aspiration cytology (FNAC), 370
 first trimester
 abnormal, 118
 diagnosis, 120–6
 history, 118–19
 laboratory analysis, 119
 physical exam, 119
 scope of, 118
 treatment, 120–6
 ultrasound, 119–20
 prenatal care, 130
 surgical abortion, 144
 ultrasound, 50
 fish lips, 32
 Fitz-Hugh-Curtis syndrome, 199–200
 5 A's, 425
 flavoxate, 226–31
 fluconazole, 246, 247–8
 fluorescent treponemal antibody absorbed (FTA-ABS), 132
 fluoroquinolones, 384
 fluoxetine, 30
 flutamide, 318, 328
 FNAC. *See* fine needle aspiration cytology
 folic acid, 110
 preconception counseling, 113
 supplementation, 110–11
 follicular-stimulating hormone (FSH), 287, 311–12, 341, 353
 genetic abnormalities of, 353
 sensitivity to, 312
 fosfomycin trometamol, 384
 fracture risk assessment, 470
 Fragile X, 113
 fragility fractures, 469
 frailty, 503
 Framingham Risk Assessment Tool, 460–1
 FRAX, 470
 annual examination, 4
 FSDS. *See* Female Sexual Distress Scale
 FSFI. *See* Female Sexual Function Index
 FSH. *See* follicular-stimulating hormone
 FTA-ABS. *See* fluorescent treponemal antibody absorbed
 functional incontinence, 221–2
 assessment, 223
 functional status, 66
 furosemide, 101
 GABA, 389
 gabapentin, 344, 485
 Gail model, 40
 galactorrhea, 165
 nonpuerperal, 374
 galactosemia, 30
 Gartner duct cysts, 243
 gas emboli, 98
 G.D. Searle and Company, 17

- general anesthesia, 147
 general examination, 62
 genetic counseling
 BRCA1, 40, 41
 BRCA2, 40, 41
 HBOC, 41
 Genetic Information and
 Nondiscrimination Act, 41
 genetic syndromes, 133
 genital arousal disorder, 264
 genital evaluation, 364
 genital outflow tract disorders, 162–3
 genital ulcers, 190–1
 genital warts, 191
 cancer and, 192
 diagnosis of, 191
 patient applied treatment, 192
 physician administered
 treatment, 192
 psychosocial issues, 191
 transmission, 191
 treatment, 192
 geriatric population, 494
 abdominal aortic aneurysm in, 499
 abdominal pain in, 502
 asymptomatic carotid artery stenosis, 499
 bad habit avoidance, 499–500
 breast cancer in, 501
 cachexia in, 496
 cardiovascular disease in, 498
 cervical cancer screening in, 500–1
 colon cancer in, 501
 coronary heart disease in, 498–9
 dental health in, 498
 end of life decision making, 503–4
 exercise, 496
 frailty in, 503
 hearing acuity in, 498
 hypertension in, 450, 498
 immunizations in, 496–7
 incontinence in, 502
 intimate partner violence, 521
 lung cancer screening, 501
 menopause and, 501
 mental health disorders in, 499
 nutrition in, 494–6
 obesity in, 496
 osteoporosis in, 499
 pelvic organ prolapse in, 502
 risk reduction in, 499–500
 screening and prevention
 strategies, 494
 sexual health of, 502–3
 skin cancer screening in, 500
 vaginal bleeding in, 501–2
 visual acuity in, 497–8
 vulvitis and, 501
 germ cell tumors, 220
 gestational age assessment, 53–4
 ectopic pregnancy and, 141–2
 prenatal care, 130
 gestational diabetes, 134
 gestational sac, 54
 in adnexa, 124
 in endometrial cavity, 121
 gestational trophoblastic disease, 352
 gestrinone, 280
 glucose tolerance test (GTT), 134
 GnRH. *See* gonadotropin-releasing hormone analogues
 gonadal dysgenesis, 162
 gonadotroph, 161
 gonadotropin, 58, 341
 complications, 304–8
 for infertility, 300–1
 mechanism of action, 301–3
 multiple gestation pregnancy and, 305–8
 outcome of treatment, 304
 plan of treatment, 303–4
 gonadotropin-releasing hormone analogues (GnRH), 259, 363, 390
 for endometriosis, 279–80
 gonorrhea, 184, 243
 epidemiology, 184
 pathophysiology, 184–5
 screening, 9, 185
 treatment, 185
 granuloma inguinale, 190
 granulomatous mastitis, 375
 Graves' disease, 350
 group B streptococcus, 134–5
 group support, 427
 GTT. *See* glucose tolerance test
 gynandroblastoma, 327
 gynecologic exam, preoperative evaluation, 62–3
 gynecologic history, preoperative evaluation, 62
 gynecologic oncologists, 220

H. influenza, 157
 haematocolpos, 363
 haemophilus influenzae type B immunization, 9
 hamartomas, 372
 Hashimoto's disease, 349
 HBOC. *See* hereditary breast and ovarian cancers
 HBPM. *See* home blood pressure monitoring
 HbsAg. *See* hepatitis B surface antigen
 hCG. *See* human chorionic gonadotropin
 health-care system, 523
 hearing acuity, 498
 heart and vascular health, annual exam, 4–7
 heavy drinking, 483
 heavy menstrual bleeding, 168
 laboratory analysis, 155
 PAG, 153
 physical exam, 154
 treatment, 156–7
 hematometra, 146
 hemorrhage
 initial management, 96–7
 investigations, 97
 office emergencies, 96
 presentation, 96
 surgical abortion, 146
 hemorrhagic cyst, 215
 of ovaries, 56
 hemostasis, 76
 heparin, 171
 hepatitis A, 113
 immunization, 9, 497
 hepatitis B, 113, 530
 immunization, 9, 497
 prenatal care, 132
 risk factors, 10
 screening, 9–10
 hepatitis B surface antigen (HbsAg), 132
 hepatitis C, 9–10
 herbal supplements, 110–11
 hereditary breast and ovarian cancers (HBOC), 39
 future research, 43
 genetic counseling, 41
 limitations of testing, 43
 populations for screening for, 40
 risk-reducing surgery, 42–3
 surveillance of carriers, 41–2
 hereditary nonpolyposis colorectal cancer (HNPCC), 3, 44–5
 herpes simplex virus (HSV), 187
 diagnosis, 187
 epidemiology, 187
 natural history, 187
 preconception counseling, 112
 prevention, 187–8
 screening, 10, 187
 treatment, 187–8
 herpes zoster immunization, 8
 hidradenitis suppurativa (HS), 245
 high grade squamous intraepithelial lesion (HSIL), 80, 87
 CIN, 86
 hip fractures, 468
 Hippocrates, 238
 hirsutism, 322
 depilation for, 329
 epilation for, 329
 in hyperandrogenism, 324
 idiopathic, 328
 local treatments, 328–9
 in PCOS, 314, 318

Index

- hirsutism (cont.)
 pharmacologic treatment of, 328
 physical exam, 324
 systemic treatments, 328
 histologic assessment, 174
 HIV. *See* human immunodeficiency virus
 HNPPC. *See* hereditary nonpolyposis colorectal cancer
 home blood pressure monitoring (HBPM), 447
 hormonal contraception, 19–23
 cardiovascular disease and, 454–5
 for endometriosis, 279
 hormonal therapy, 204–5
 cardiovascular disease and, 454–5
 for hypertension, 451
 hormones. *See also specific hormones*
 infertility and, 287–8
 levels in menopause, 343
 ovaries producing, 58
 testing, 351
 horseshoe kidney, 362
 hot flushes, 344, 345
 HPV. *See* human papilloma virus
 HS. *See* hidradenitis suppurativa
 HSG. *See* hysterosalpingogram
 HSIL. *See* high grade squamous intraepithelial lesion
 HSV. *See* herpes simplex virus
 Hulka Clip, 23
 human chorionic gonadotropin (hCG), 53, 141–2, 303
 human immunodeficiency virus (HIV), 30, 529
 CIN and, 86–8
 contraception and, 18
 epidemiology, 193–4
 pathophysiology, 194
 preconception counseling and, 106
 prenatal care, 132, 134–5
 prevention, 194
 risk factors, 10, 193–4
 screening, 10, 194
 human papilloma virus (HPV), 2–3, 80, 191
 classification of, 81
 high-risk subtypes, 81–2
 immunizations, 8
 pregnancy and, 192
 screening, 82
 hydatidiform mole, 54
 hydrochlorothiazide, 448–9
 hydrocortisone, 251
 for anaphylaxis, 97–8
 hyperandrogenism, 322
 acne in, 324
 adrenal disorders and, 327
 alopecia in, 324
 androgen receptor antagonist for, 328
 causes of, 324
 clinical manifestations, 322
 clitoromegaly in, 325
 COC for, 328
 congenital adrenal hyperplasia and, 327
 Cushing syndrome and, 327–8
 ethnicity and, 323–4
 family history and, 323–4
 hirsutism in, 324
 history, 323–4
 laboratory analysis, 325–7
 local treatments, 328–9
 medical history, 324
 ovarian neoplasms and, 327
 patient history, 324
 PCOS and, 313
 physical exam, 324
 prevention, 329
 scope of, 323
 screening, 329
 systemic treatments, 328
 treatment, 327
 hyperemesis, 352
 hyperprolactinemia, 331, 333, 354
 causes, 332, 333
 clinical presentation, 331–2
 follow-up, 334–6
 pregnancy and, 336–7
 prevalence of, 331
 treatment, 334–6
 hyperprolactinoma
 diagnostic workup, 333–4
 medications causing, 332
 natural history, 333
 osteoporosis and, 332
 hypertension
 annual examination, 4–6
 basic workup, 5–6
 causes, 6
 childbearing potential and, 450
 definition, 443
 diagnosis, 445
 in geriatric populations, 450, 498
 hormonal therapy for, 451
 laboratory analysis in, 446
 lifestyle modifications for management of, 6, 447
 masked, 443–4
 medications and, 445
 patient history, 445
 PCOS and, 316
 pharmacologic agents, 448–50
 physical examination, 446
 preconception counseling and, 106
 pregnancy and, 450–1
 prevalence of, 443
 pseudohypertension, 444
 resistant, 444
 risk factors, 444–5
 scope of problems, 443
 treatment, 5–7, 447
 white-coat, 444
 hyperthyroidism, 350–2
 causes, 350
 gestational trophoblastic disease, 352
 hormonal testing for, 351
 pregnancy and, 352
 subclinical, 351
 symptoms of, 351
 hypnotherapy, 427
 hypocalcemia, 471
 hypogastric pain, 435
 hypogonadism
 central, 353
 evaluation schematic, 354
 hypogonadotropic hypogonadism, 353
 acquired, 354
 congenital, 353–4
 ovulation induction in, 298
 hypothalamic amenorrhea, 160–1, 353–4
 hypothalamic dysfunction, 172
 hypothyroidism, 113, 349–50
 autoimmune, 349
 iatrogenic, 349
 pregnancy and, 350
 prevalence of, 349
 symptoms, 349
 hypoxia, 99
 hysterectomy, 2–3, 255–6
 abnormal uterine bleeding, 178–9
 embolization versus, 181
 for endometriosis, 280
 infection after, 68–9
 for Lynch syndrome, 45
 menopause and, 342–3
 preoperative evaluation, 64
 hysterosalpingogram (HSG), 23–4, 292–3
 hysteroscopic sterilization, 23–4, 74–6
 contraindications, 75
 counseling, 75
 office procedures, 74–6
 scheduling, 75
 hysteroscopy
 equipment list, 73
 fertility scan, 293–4
 office procedures, 72–4
 outpatient, 293–4
 hysterosonogram, 173
 iatrogenic hypothyroidism, 349
 IBD. *See* inflammatory bowel disease
 idiopathic hirsutism, 328
 idiopathic pelvic pain, 441
 illicit drug use, annual examination, 11
 imiquimod, 192
 immigrant women, 520

- immunity testing, 113
 immunization
 annual examination and, 8–9
 in geriatric population, 496–7
 haemophilus influenzae type b, 9
 hepatitis A, 9, 497
 hepatitis B, 9, 497
 herpes zoster, 8
 HPV, 8
 influenza, 8
 meningococcal, 9
 MMR, 8
 pneumococcal, 114
 Td/Tdap, 8
 for travel, 8
 varicella, 8
 zoster, 8
 immunosuppression, 354
 imperforate hymen, 363
 amenorrhea, 163
 Implanon, 22
 incomplete surgical abortion, 146
 indeterminate breast masses, 371
 indwelling catheters, 386
 infection prophylaxis, 68–9
 infection screening
 annual examination, 9–11
 prenatal care, 131–2
 infectious agents, 111–12
 infertility. *See also* subfertility
 disability and, 514–15
 endometriosis and
 ART pretreatment, 282
 surgical treatment, 281–2
 treatment, 281
 hormonal profile of female
 patients, 287
 hormonal profile of male partner,
 287–8
 outpatient management, 297
 anti-estrogens in, 298–9
 aromatase inhibitors, 300
 exercise for, 298
 gonadotropin for, 300–1
 lifestyle modifications, 297
 metformin, 299–300
 smoking cessation, 298
 weight reduction for, 297
 PCOS and, 313
 semen analysis in, 287–8
 ultrasound and, 58–9
 inflammatory bowel disease (IBD), 437
 inflammatory carcinoma of breast, 375
 influenza immunizations, 8
 informative model, 539
 informed consent
 abortion, 140
 preoperative evaluation, 64
 Inhibin, 312
 injectable Progestin, 20–1
 intermenstrual bleeding, 168
 internal iliac artery, 179
 interpersonal therapy (IPT), 401
 interpretive model, 539
 interstitial pregnancy, 54–5
 intimate partner violence
 in adolescents, 520
 annual examination, 11
 characteristics of, 518
 diagnosis, 521
 disability, 520–1
 geriatric population, 521
 health-care system and, 523
 health consequences of, 519
 in immigrant women, 520
 management, 521–3
 preconception counseling, 111
 prenatal care screening, 131
 reproductive coercion in, 519
 scope of, 518
 screening, 521
 sexual dysfunction and, 269
 support in, 522
 types of, 519
 intraductal papilloma, 374
 intrauterine balloon, 74
 intrauterine pregnancy, 52–4
 assessment of, 54
 failure, 122
 follow-up, 123
 intravenous pyelogram, 363
 IPT. *See* interpersonal therapy
 irbesartan, 448–9
 iron, 110
 iron deficiency anemia, 113
 irregular menses, 343
 irritable bowel syndrome, 202, 203, 436
 management options, 204
 isthmocoele, 52
 IUDs, 18
 complications, 22
 copper, 21
 levonorgestrel, 176
 menorrhagia and, 259
 ultrasound placement of, 78–9
 IUP, early detection, 120–1
 Jarisch-Herxheimer reaction, 190
 justice, 536
 Kaletra, 530
 Kallmann's Syndrome, 161
 defects in, 353
 karyotype determination, 133
 Kevorkian forceps, 243
 Klebsiella granulomatis, 190
 laboratory analysis
 abnormal uterine bleeding, 172
 delayed puberty, 156
 depression, 396–7
 first trimester, abnormal, 119
 heavy menstrual bleeding, 155
 hyperandrogenism, 325–7
 in hypertension, 446
 osteoporosis, 470
 PAG, 155
 precocious puberty, 156
 preconception counseling, 112–13
 prenatal care, 131–2
 sexual assault, 529
 in UTI, 382
 vulvovaginitis, 155–6, 242–3
 lactating adenomas, 372
 lactation, 26. *See also* breastfeeding
 anatomy and physiology of, 28–9
 breast evaluation and, 33
 colostrum, 28–9
 milk, 28–9
 supply, 33–4
 relactation, 35
 lactational amenorrhea, 26–8
 LactMed, 30
 lactogenesis
 stage I, 28–9
 stage II, 28–9
 lamivudine, 530
 lanugo hair, 408–9
 laparoscopic diagnosis, 277
 laparoscopic sterilization, 23
 laparoscopic uterosacral nerve abla-
 tion, 280
 LARCS. *See* long-acting reversible
 contraception
 LAST. *See* Lower Anogenital
 Squamous Terminology
 last menstrual period (LMP) date, 118
 last normal menstrual period
 (LNMP), 53
 LEAF. *See* Lifestyle Eating and Fitness
 leakage prevention products, 229
 LEEP. *See* loop electrosurgical excision
 procedure
 left iliac pain, 435
 legal issues
 sexual assault, 530–1
 substance abuse disorders and, 491
 leiomyomas, 169–70
 ablation, 179
 leukotriene, 437
 levator ani, 233
 levofloxacin, 384, 385
 levonorgestrel, 21, 22
 levonorgestrel IUD, 176
 LGV. *See* lymphogranuloma venereum
 LH. *See* luteinizing hormone
 liberty, 536
 lichen sclerosus, 157, 207, 244–5
 lichen simplex chronicus, 244
 Lidocaine, 76

Index

- Lifestyle Eating and Fitness (LEAF), 460
- lifestyle management
- cardiovascular disease, 458–61
 - for osteoporosis, 474–6
- lifestyle modifications
- BRCA1, 43
 - BRCA2, 43
 - in familial hypercholesterolemia, 461
 - for hypertension, 6, 447
 - for infertility, 297
 - for obesity, 418
 - for UI, 226–7
- Li-Fraumeni syndrome, 43–4
- lipid classification, 7
- lipid screening, 455
- lisinopril, 448–9
- lithium, 107, 355
- LMP date. *See* last menstrual period date
- LNMP. *See* last normal menstrual period
- local anaesthetic toxicity
- initial management, 99–100
 - investigations, 100
 - office emergencies, 99
 - presentation, 99–100
- long-acting reversible contraception (LARCS), 18, 21–2
- loop electrosurgical excision procedure (LEEP)
- for CIN, 88
 - counseling, 76
 - hemostasis, 76
 - office procedure, 76–7
- lorazepam, 91, 95–6
- losartan, 448–9
- low body weight, 108
- low grade squamous intraepithelial lesion (LSIL), 80
- findings with no lesion, 83
 - pregnancy and, 85
 - in women aged 21–4, 84
- Lower Anogenital Squamous Terminology (LAST), 80
- lower urinary tract symptoms, 223
- LS. *See* Lynch syndrome
- LSIL. *See* low grade squamous intraepithelial lesion
- Lugol's solution, 76
- lung cancer
- annual examination, 3
 - geriatric population, 501
- lungs, 236
- luteinizing hormone (LH), 156, 287, 311–12, 353
- lymphogranuloma venereum (LGV), 190–1
- Lynch syndrome (LS), 44–5
- BSO for, 45
 - hysterectomy for, 45
 - risk reduction, 45
 - screening, 44
 - high-risk populations, 44
- magnesium, 91
- magnesium sulfate, 95
- magnetic resonance imaging (MRI), 174
- in abnormal artery embolization, 179
 - breast complaints and, 370
 - in endometriosis, 278
 - of pelvic masses, 213
- magnetic therapy, 228
- male condom, 19, 187–8
- male fertility, 286
- male vasectomy, 24
- malignant pathologic ovarian masses, 217–19
- mammary duct ectasia, 374
- mammography
- annual examination, 2
 - breast complaints and, 369
 - indications for, 369
- marijuana abuse
- behavioral therapy for, 489
 - epidemiology, 488–9
 - intoxication, 489
 - pharmacotherapy, 489
 - withdrawal, 489
- masked hypertension, 443–4
- mastalgia, 375–6
- diagnosis, 377
 - patient history, 376
 - physical exam, 376–7
 - treatment, 368–77
- mastitis, 28, 375
- breastfeeding and, 32–3
 - granulomatous, 375
 - nonlactational, 375
 - supportive measures for, 33
- maternal age, 110
- maternal death, 17
- maternal illness, 34
- maternal mortality, 129
- maternal nutrition, 34
- mature cystic teratomas, 215–17, 218
- Mayer Rokitansky Kuster Hauser Syndrome (MRKH), 362
- measles, mumps, rubella (MMR), 8, 496–7
- Mechanical Vacuum Aspirator (MVA), 144, 145
- medical abortion
- candidates for, 142
 - complications, 143–4
 - evidence-based, 142
 - follow-up, 143
 - infections, 143
 - medications, 142
 - pain management, 146–7
 - patient expectations, 143
 - regimens, 142
 - surgical abortion and, 141
- medical assessment, 129–30
- medical evaluation, abortion, 141
- medical history
- hyperandrogenism, 324
 - preconception counseling and, 105, 110
 - preoperative evaluation, 61–2
 - in subfertility, 285–6
- medroxyprogesterone, 317
- Meigs' Syndrome, 216
- memory
- cognitive dysfunction and, 345
 - menopause and, 345
- MEN. *See* multiple endocrine neoplasia
- meningococcal immunization, 9
- menometrorrhagia, 168
- menopause, 341
- bone density and, 346
 - cardiovascular disease, 346
 - geriatric population and, 501
 - hormone levels in, 343
 - hysterectomy and, 342–3
 - memory and, 345
 - mood disorders, 345–6
 - obesity, 420–1
 - osteoporosis and, 346
 - transition, 341–2
 - UTI and, 385
 - vasomotor symptoms, 343–4
- menorrhagia, 168
- definition, 257
 - IUDs and, 259
 - in PAG, 151
 - progesterone and, 259
 - in uterine leiomyoma, 257
- menstrual cycle, 17
- normal, 160
 - PCOS and, 317
- menstrual history
- PAG, 153
 - in preconception counseling, 105
- mental health disorders
- in geriatric population, 499
 - preconception counseling, 107
- mental illness, 483
- mental status, in POP, 236
- Mental Status Exam (MSE), 396
- mercury exposure, 112
- mesonephric ducts, 360–1
- metabolic syndrome
- criteria for, 313
 - PCOS and, 313, 318–19

- metformin, 318, 319
 complications, 300
 for infertility, 299–300
 mechanism of action, 299–300
 outcome of treatment, 300
 plan of treatment, 300
- methadone, 487
- methamphetamines, 488
- methimazole, 351
- methotrexate, 54, 125
- methoxamine, 230
- metronidazole, 186, 193
- metrorrhagia, 168
- MI. *See* myocardial infarction
- miconazole, 246–8
- microadenoma, 333–4
- microcytic anemia, 132
- midazolam, 91, 95–6
- mifepristone, 142, 143–4, 259
- migratory abdominal pain, 434
- milk, 28–9
 fistula, 33
 production, 28–9
 storage of, 35
 supply, 33–4
- mill wheel murmur, 98–9
- mirtazapine, 400
- miscarriage, 105–6
- misoprostol, 142, 143–4
- missed abortion
 diagnosis, 121–3
 treatment, 121–3
- mixed gonadal dysgenesis, 364
- mixed incontinence, 221
- MMR. *See* measles, mumps, rubella
- modifiable risk, 68
- moexipril, 448–9
- molar pregnancy
 diagnosis, 123
 treatment, 123
 ultrasound, 123
- Mondor disease, 378
- mono-manual exam, 269–70
- Monsel's paste, 76
- mood disorders, 345–6
- morcellation, 178–9
 preoperative evaluation, 63–4
- morphine, 31
- mosaicism, 162
- motion tenderness, 57
- MRI. *See* magnetic resonance imaging
- MRKH. *See* Mayer Rokitansky Kuster Hauser Syndrome
- MSE. *See* Mental Status Exam
- mucinous cystadenomas, 216–17
- Mullerian agenesis, 152–3
 amenorrhea, 163–4
- Mullerian anomalies, 361–3
- multifetal pregnancy, 53
- multiple endocrine neoplasia (MEN), 357
 tumors associated with, 357
- multiple gestation pregnancy, 305–8
- musculoskeletal problems, 202
- musculoskeletal system, 441
- MVA. *See* Mechanical Vacuum Aspirator
- myocardial infarction (MI)
 initial management, 93–4
 investigations, 94
 office emergencies, 92–3
 presentation, 94
- myolysis, 178
- myoma, 51–2
 FIGO classification, 169
 uterine, 215
- myomectomy, 178
- myotonic dystrophy, 109
- Myriad Genetic Laboratories model, 40
- NAAT. *See* nucleic acid amplification tests
- Nabothian follicles, 52
- nalbuphine, 31
- naltrexone, 485
- NAS. *See* neonatal abstinence syndrome
- National Cholesterol Education Program (NCEP), 460–1
- National Institute of Clinical Excellence (NICE), 224
- NCEP. *See* National Cholesterol Education Program
- necrotizing enterocolitis, 27, 28
- negative for intraepithelial lesion (NILM), 80
- Neisseria gonorrhoea*, 155–6
- neonatal abstinence syndrome (NAS), 30
- neo-vagina, 362
- nephrogenic diabetes insipidus, 356
- nephrolithiasis, 437–8
- neural tube defect (NTD), 131
- neurological assessment, 225
- neuromodulation, 205
- neuropathic pain, 205
- neurostimulation, 228–9
- neurosyphilis, 188–9
- Nexplanon, 22
 office procedure, 77–8
 removal, 78
- NICE. *See* National Institute of Clinical Excellence
- nicotine, 424
 replacement, 427, 428
- nifedipine, 448–9
- night sweats, 344
- NILM. *See* negative for intraepithelial lesion
- nipple discharge, 372
 breastfeeding and, 33
 clinically benign, 374
 clinically suspicious, 374–5
 evaluation of, 374
 pathologic, 374–5
 patient evaluation, 373
 patient history, 373
 physical exam, 373–4
 scope of problem, 372
 stratification of, 373
- nipple pain, 32
- nipple piercings, 31
- nitrofurantoin, 384
- nonlactational mastitis, 375
- non-maleficence, 535–6
- nonovarian adnexal mass, 215
- nonpregnant state confirmation, 18–19
- nonpuerperal galactorrhea, 374
- nonsteroidal anti-inflammatory drugs (NSAIDs), 176–7, 200, 377
 for endometriosis, 279
- noradrenaline, 230
- norelgestromin, 20
- normal ovulation physiology, 311–12
- normogonadotropic induction, 298
- Norplant, 22–3
- North American Menopause Society, 24
- NSAIDs. *See* nonsteroidal anti-inflammatory drugs
- NTD. *See* neural tube defect
- nucleic acid amplification tests (NAAT), 185
- nutrition
 annual examination, 12–13
 in geriatric population, 494–6
 osteoporosis and, 475
 preconception counseling and, 110
- NuvaRing, 20
- nystatin, 246–8
- OAB. *See* overactive bladder
- obesity, 414
 annual examination, 12–14
 behavioral therapy for, 417
 BMI classification, 416
 childhood, 27
 contraception and, 419–21
 costs of, 416
 diagnosis of, 416
 ethnicity and, 414
 evaluation of, 416
 in geriatric population, 496
 lifestyle modifications for, 418
 management of, 14
 menopause, 420–1
 PCOS and, 312
 physician challenges in, 421
 preconception counseling and, 108
 pregnancy and, 418–19

Index

- obesity (cont.)
 prevalence of, 414, 415–16
 race and, 414
 risk factors, 417
 scope of problem, 414–16
 screening for, 416
 treatment for, 417–18
- obstetric history, 62
- OCP. *See* oral contraceptive pill
- office, 29–30
- office emergencies, 90
 acute asthma, 94–5
 acute coronary syndrome, 92–3
 anaphylaxis, 97
 cardiac arrest, 92
 common, 90
 embolic complications, 98
 general planning for, 90–2
 hemorrhage, 96
 local anaesthetic toxicity, 99
 MI, 92–3
 seizures, 95
 vasovagal reactions, 100
 water intoxication syndrome, 100–1
- office procedures, 72
 endometrial ablation, 74
 hysteroscopic sterilization, 74–6
 hysteroscopy, 72–4
 loop electrosurgical excision procedure, 76–7
 Nexplanon, 77–8
 ultrasound, 78–9
 vulvar biopsy, 77
- ofloxacin, 384
- OHSS. *See* ovarian hyperstimulation syndrome
- oligomenorrhagia, 168
- oligospermia, 287
- opiate abuse
 behavioral therapy, 488
 epidemiology, 487
 pharmacotherapy, 487–8
 pregnancy and, 490
 symptoms of, 487
 withdrawal, 487
- optimization, 68
- oral contraceptive pill (OCP), 17,
 19–20, 156–7, 451
 BRCA1 and, 42
 BRCA2 and, 42
 cardiovascular disease and, 454–5
 chemoprevention, 42
 combined oral, 328
 contraindications, 20
 PCOS and, 317
 for PMS/PMDD, 390–1
- orgasmic disorder, 264, 271
- Ortho Evra, 20
- ospemifene, 207
- osteo-anabolic medication, 474
- osteonecrosis of jaw, 477–8
- osteoporosis
 alcohol and, 476
 antiresorptive medications for, 472–4
 bisphosphonates for, 472–3
 caffeine intake, 475–6
 calcitonin for, 474
 calcium and, 474–5
 denosumab and, 473–4
 densitometric diagnosis, 469
 distal radius fractures, 468
 estrogen for, 474
 exercise and, 476
 fall risk in, 470–1
 fracture risk assessment in, 470
 fragility fractures and, 469
 in geriatric population, 499
 hip fractures and, 468
 hyperprolactinoma and, 332
 impact of, 468
 laboratory exams, 470
 lifestyle management for, 474–6
 medication studies, 472
 menopause and, 346
 nutrition and, 475
 osteo-anabolic medication for, 474
 prevention, 478
 proximal humerus fractures
 and, 468
 screening, 4, 478
 smoking and, 476
 sodium and, 475–6
 treatment, 4, 346
 vertebral fractures, 468
 vitamin D and, 475
- otitis media, 27
- ovarian cancer, 27
 annual examination, 3
 BSO for, 43
 genetic testing, 219
 screening, 41–2
- ovarian cysts, 215
- ovarian disorders, 161–2
- ovarian fibromas, 57–8, 216
- ovarian hyperstimulation syndrome (OHSS), 304, 307
- ovarian masses, 215
 benign pathologic, 215–17
 malignant pathologic, 217–19
- ovarian neoplasms, 58
 hyperandrogenism and, 327
- ovarian reserve assessment, 291–2
- ovarian torsion, 440
- ovaries, 55–8
 ascites and, 57
 hemorrhagic cyst of, 56
 hormone producing tumors, 58
 internal echo-structure, 57
 motion tenderness, 57
 normal, 55
- overall appearance, 57
 shadowing, 57
 size, 57
- overactive bladder (OAB), 221
- overflow incontinence, 221
- overweight, 416
- ovulation
 induction
 in hypogonadotropic hypogonadism, 298
 in normogonadotropic induction, 298
 normal, 311–12
 in PCOS, 317–18
- oxybutynin, 230
- oxytocin, 26–8
- pacifiers, 31–2
- PAD test, 226
- PAG. *See* Pediatric and Adolescent Gynecology
- pain management. *See also* abdominal pain
 abortion, 146
 medical abortion, 146–7
 surgical abortion, 147
- painful bladder syndrome, 202, 204, 438
- PAIS. *See* partial androgen insensitivity
- PALM-COEIN, 169–71
- palpation, 368–9
- Pap smears, 131
- Pap test, 2–3
- paracervical block, 147
- parathyroid hormone (PTH), 471
- partial androgen insensitivity (PAIS), 364
- past obstetric history, 109
- paternal age, 110
- paternalistic model, 538–9
- patient education
 abortion, 140
 sexual assault, 527
- patient history
 abnormal uterine bleeding, 171–2
 age in, 367
 amenorrhea, 165
 Basic well-woman examination, 1
 breast complaints, 367–8
 dyspareunia, 206–7
 first trimester, abnormal, 118–19
 hyperandrogenism, 324
 hypertension, 445
 mastalgia, 376
 PAG, 153
 pelvic organ prolapse, 235–6
 urinary incontinence, 222–3
 vulvovaginitis, 153, 242
- patient risk status, 66

- PCOS. *See* polycystic ovarian syndrome
- PCR. *See* polymerase chain reaction
- peak systolic velocity (PSV), 291–2
- Pearl Index (PI), 17
- Pediatric and Adolescent Gynecology (PAG), 151
- approach, 152–3
 - confidentiality and, 152
 - delayed puberty, 151–2, 153
 - heavy menstrual bleeding, 153
 - laboratory analysis, 155
 - menorrhagia and, 151
 - menstrual history, 153
 - patient history, 153
 - physical examination, 154
 - precocious puberty and, 152, 154
 - prevention, 158
 - scope of, 151
 - screening, 158
 - vulvovaginitis in, 151, 153
- pedunculated fibroids, 256–7
- pelvic examination, 2
- pelvic floor muscle exercises (PFME), 227
- pelvic floor muscle function, 224
- pelvic inflammatory disease (PID)
- abdominal pain in, 439
 - clinical presentation, 186
 - diagnosis, 186
 - epidemiology, 185–6
 - prevention, 186
 - risk factors, 199
 - treatment, 186, 200
- pelvic masses, 211
- adnexal torsion and, 214
 - CT, 212–13
 - differential diagnosis, 212
 - ectopic pregnancy and, 213–14
 - imaging, 212–13
 - initial evaluation of, 211
 - management of, 213
 - MRI of, 213
 - PET of, 213
 - physical exam, 212
 - systems findings, 211
 - transvaginal ultrasound for, 212
 - tubo-ovarian abscess and, 214–15
 - ultrasound, 212–13
 - uterine myomas and, 215
- pelvic organ prolapse, 223, 233
- abdominal issues, 236
 - anatomy in, 233–4
 - cardiovascular system in, 236
 - epidemiology of, 234
 - in geriatric population, 502
 - lungs in, 236
 - mental status, 236
 - patient history, 235–6
 - pelvic issues in, 236–8
 - pessary for, 238–40
 - physical exam, 236
 - quantification system, 237
 - risk factors for, 234–5
 - sexual function and, 236
 - skeletal/gait issues, 236
 - surgery for, 240
 - treatment, 238
- pelvic organ scanning, 51–2
- pelvic pain
- acute, 198
 - approach to, 198
 - clinical examination, 199–200
 - differential diagnosis, 199
 - history, 199
 - imaging, 200
 - invasive diagnosis, 200
 - investigations, 200
 - medical treatment, 200
 - prevention, 201
 - scope, 198
 - sexual history and, 199
 - surgical treatment, 200–1
 - ultrasound, 200
- chronic
- analgesia for, 204
 - approach to, 201–2
 - causes of, 201
 - clinical examination, 203
 - common conditions of, 202
 - history, 202–3
 - hormonal based treatment, 204–5
 - invasive diagnosis, 203
 - investigations, 203
 - medical treatment of, 205
 - neuromodulation for, 205
 - neuropathic pain, 205
 - physiotherapy, 205
 - prevention, 205
 - psychological therapy, 205
 - red flag symptoms, 202
 - scope of problem, 201
 - surgery, 205
 - treatment, 203–4
- pelvic pressure, 257
- pelvic ultrasound, 163
- indications for, 50
- Pen II Risk model, 40
- penicillin, 134–5, 189–90
- perimenopause, 402
- perindopril, 448–9
- perineal body descent, 235
- perioperative assessment, 66
- peripartum hemorrhage, 129
- peripartum varicella, 30
- persistent sexual arousal disorder, 264
- pessary
- for pelvic organ prolapse, 238–40
 - space occupying, 239
 - support, 238–9
- pesticide exposure, 112
- PET. *See* positron emission tomography
- Peutz-Jeghers syndrome (PJS), 45
- PFME. *See* pelvic floor muscle exercises
- phenylketonuria, 108
- phenylpropanolamine, 230
- phosphodiesterase inhibitors, 271
- Phyllodes tumors, 372
- physical examination
- abnormal uterine bleeding, 171–2
 - acne, 324
 - alopecia, 324
 - amenorrhea, 165
 - Basic well-woman examination, 1
 - breast complaints, 368
 - delayed puberty, 154
 - depression and, 395–6
 - first trimester, abnormal, 119
 - heavy menstrual bleeding, 154
 - hirsutism, 324
 - hyperandrogenism, 324
 - hypertension, 446
 - mastalgia, 376–7
 - nipple discharge, 373–4
 - PAG, 154
 - pelvic masses, 212
 - pelvic organ prolapse, 236
 - precocious puberty, 154–5
 - preconception counseling, 112
 - prenatal care, 131, 132–3
 - in preoperative evaluation, 62
 - sexual assault, 527
 - sexual dysfunction, 269–70
 - subfertility, 286
 - in uterine leiomyoma, 257–8
 - UTI, 382
 - vulvovaginitis, 154, 242
- physical therapy, 227
- physiologic ovarian cysts, 215
- phytoestrogens, 344
- PI. *See* Pearl Index
- PID. *See* pelvic inflammatory disease
- pituitary
- abnormalities, 161
 - amenorrhea and, 161
- pituitary-ovarian (PTO) axis, 170–1
- pivmecillinam, 384
- PJS. *See* Peutz-Jeghers syndrome
- placenta, 134
- plateau, 263
- PLISSIT model, 266–7
- plugged duct, 28
- PMDD. *See* Premenstrual Dysphoric Disorder
- PMS. *See* Premenstrual Syndrome
- pneumococcal immunization, 114
- podophyllotoxin, 192

Index

- polycystic ovarian syndrome (PCOS),
 55–6, 172, 286, 287, 297, 311,
 323, 453–4
 androgen and, 312
 blood testing, 315
 clinical findings, 311
 depression and, 316
 diabetes and, 316
 diagnosis, 313–15
 evaluation, 313–15
 examination considerations, 314
 hirsutism in, 314, 318
 hyperandrogenism and, 313
 hypertension and, 316
 induction of ovulation in, 317–18
 infertility and, 313
 long-term consequences, 315–16
 management, 316–17
 menstrual regulation, 317
 metabolic syndrome and, 313,
 318–19
 obesity and, 312
 oral contraceptives and, 317
 pathophysiology of, 312–13
 pregnancy and, 316
 presentation, 313
 prevalence of, 311
 scope of, 311
 subfertility and, 292
 ultrasound in, 314, 317
 polydipsia, 355
 polymerase chain reaction (PCR),
 249–50
 polyuria, 355
 positron emission tomography
 (PET), 213
 post micturition, 223
 post term pregnancy management, 136
 postpartum depression, 26–8, 30, 402
 post-traumatic stress disorder, 531
 post-void residual (PVR), 225–6
 precocious puberty
 classification, 152
 laboratory analysis, 156
 PAG and, 152, 154
 physical exam, 154–5
 treatment, 158
 preconception counseling, 8
 alcohol abuse, 111
 anemia, 107
 asthma, 107
 cancer, 107
 cardiac disease, 108
 cytomegalovirus, 111–12
 dental health, 111
 diabetes mellitus and, 105–6
 drug abuse, 111
 environmental exposures, 111–12
 epilepsy and, 106–7
 ethnicity, 109–10
 exercise and, 111
 family history, 109–10
 folic acid, 113
 HIV and, 106
 HSV, 112
 hypertension and, 106
 infectious agents, 111–12
 interventions, 113
 intimate partner violence, 111
 laboratory tests, 112–13
 low body weight and, 108
 maternal age, 110
 medical history in, 105, 110
 medication use and, 110
 menstrual history in, 105
 mental health disorders, 107
 mercury exposure, 112
 myotonic dystrophy, 109
 nutrition and, 110
 obesity and, 108
 partner in, 105
 paternal age, 110
 pesticide exposure, 112
 phenylketonuria, 108
 physical examination, 112
 renal disease, 108
 scope of, 105
 supplements, 110–11
 systemic lupus erythematosus, 107
 thromboembolic disease, 109
 thyroid disease, 107–8
 tobacco, 111
 toxoplasmosis, 111–12
 vaccination, 113
 preeclampsia, 450, 453–4
 prenatal care, 131
 pregabalin, 205
 pregnancy
 abdominal, 55
 in adolescents, 490
 bromocriptine and, 336
 cabergoline and, 336
 cervical, 55
 contaminants, 112
 dating, 119
 depression and, 402
 diabetes insipidus and, 356
 dopamine agonists and, 337
 early, 438–9
 early delivery, 136
 ectopic, 53, 54–5, 118
 diagnosis, 123–6
 gestational age assessment and,
 141–2
 pelvic masses and, 213–14
 risk factors, 119
 treatment, 123–6
 embryonic period, 53
 exercise and, 111
 failure, 122
 HPV and, 192
 hyperprolactinemia and, 336–7
 hypertension and, 450–1
 hyperthyroidism and, 352
 hypothyroidism and, 350
 interstitial, 54–5
 intrauterine, 52–4
 assessment of, 54
 failure, 122
 follow-up, 123
 LSIL and, 85
 molar
 diagnosis, 123
 treatment, 123
 multifetal, 53
 multiple gestation, 305–8
 nonpregnant state confirmation,
 18–19
 normal, 119
 obesity and, 418–19
 opiate use and, 490
 PCOS and, 316
 planning, 8, 105
 post term management, 136
 ruptured ectopic, 126
 sexual dysfunction and, 268–9
 smoking cessation and, 430
 symptomatic early, 125
 termination, 139
 ultrasound and, 50, 52–4
 of undetermined location, 124
 unintended, 139
 adverse health events, 106
 continuation of, 139
 contraception counseling
 and, 148
 UTI and, 385
 premature infants, 35
 premature ovarian failure
 amenorrhea, 162
 diagnosis of, 162
 treatment, 162
 Premenstrual Dysphoric Disorder
 (PMDD), 388, 401–2
 diagnosis, 388–9, 391
 etiology, 389–90
 oral contraception for, 390–1
 scope of problem, 388
 SSRIs for, 390
 treatment, 390–2
 Premenstrual Syndrome (PMS), 388
 diagnosis, 388–9, 391
 etiology, 389–90
 oral contraception for, 390–1
 scope of problem, 388
 SSRIs for, 390
 treatment, 390–2
 prenatal care
 aneuploidy screening, 133
 antenatal testing, 135

Index

- asymptomatic bacteruria
 screening, 132
 cervical cancer screening, 132
 cervical lengths, 134
 complete blood count, 132
 congenital malformation and, 131
 delivery timing, 135–6
 fetal anatomic survey, 133–4
 first trimester, 130
 genetic syndromes, 133
 gestational age assessment, 130
 gestational diabetes screening, 134
 group B streptococcus, 134–5
 hepatitis B, 132
 HIV, 132, 134–5
 infection screening, 131–2, 134–5
 initial visit, 131
 intimate partner violence
 screening, 131
 karyotype determination, 133
 laboratory evolution, 131–2
 maternal mortality and, 129
 medical assessment, 129–30
 noninvasive aneuploidy
 screening, 133
 physical exam, 131, 132–3
 preeclampsia, 131
 prior obstetric outcome, 130–1
 randomized clinical trials, 129
 Rh immunoprophylaxes, 134
 second trimester, 133
 spontaneous preterm delivery
 and, 130
 success of, 129
 syphilis, 132, 134–5
 third trimester, 134–6
 ultrasound for aneuploidy, 133–4
 prenatal vitamins, 110–11
 preoperative evaluation, 61
 adnexal mass, 63
 blood loss preparation, 69–70
 diagnostic risk assessment, 63
 emotional considerations, 64–5
 functional status, 66
 general examination, 62
 gynecologic exam, 62–3
 gynecologic history, 62
 history, 61
 hysterectomy, 64
 informed consent, 64
 medical history, 61–2
 modifiable risk, 68
 morcellation, 63–4
 obstetric history, 62
 optimization, 68
 patient risk status, 66
 physical examination in, 62
 procedure risk, 66–8
 review of systems, 62
 surgical approach, 64
 surgical site infection prophylaxis, 68–9
 venous thromboprophylaxis, 69
 preoperative testing, 65
 selection, 65
 presacral neurectomy, 280
 preventive health care, 1
 prima facie obligations, 537
 primary amenorrhea, 160
 primary syphilis, 188
 prior obstetric outcome, 130–1
 procedure risk, 66–8
 progesterone
 in endometriosis, 275
 menorrhagia and, 259
 progestins, 19, 176, 344
 progestogens, 204–5, 279
 prolactin, 161, 315
 function of, 331
 prolactinemia, 172
 prolactinoma, 161, 172,
 335–6
 prompted voiding, 228
 propylthiouracil (PTU), 351
Proteus mirabilis, 381
 prothrombin time (PT), 65
 proximal humerus
 fractures, 468
 pseudoephedrine, 230
 pseudohypertension, 444
 PSV. *See* peak systolic velocity
 psychological issues
 of amenorrhea, 166
 genital warts, 191
 psychology
 chronic pelvic pain, 205
 sexual dysfunction and, 267
 psychotherapy, 400–1
 PT. *See* prothrombin time
 PTH. *See* parathyroid hormone
 PTO. *See* pituitary-ovarian axis
 PTU. *See* propylthiouracil
 puberty
 congenital adrenal hyperplasia and,
 357–8
 delayed, 353–4
 laboratory analysis, 156
 PAG and, 151–2, 153
 physical exam, 154
 treatment, 157–8
 precocious
 classification, 152
 laboratory analysis, 156
 PAG and, 152, 154
 physical exam, 154–5
 treatment, 158
 virilization at, 357–8
 punch biopsy, 77
 PVR. *See* post-void residual
 pyelonephritis, 384
 quality of life questionnaire (QoL), 225
 quinapril, 448–9
 race, 414
 radiographic studies, 65
 radiological procedures, 179
 RADIUS trial, 133–4
 raloxifene, 42
 ramipril, 448–9
 randomized clinical trials, 129
 rape trauma syndrome, 531
 rapid plasma reagin (RPR), 132
 reactive oxygen species (ROS), 274–5
 recessive genetic traits, 109
 rectal examination, 224–5
 referrals
 for alcohol use disorder, 486
 to gynecologic oncologists, 220
 Reifenshtein Syndrome, 358
 relactation, 35
 renal function, 113
 abdominal pain and, 437–8
 anomalies, 362
 in anorexia nervosa, 410
 in bulimia nervosa, 410
 in eating disorders, 410
 preconception counseling, 108
 reproductive coercion, 519
 reproductive lifecycle
 anorexia nervosa and, 409–10
 bulimia nervosa and, 409–10
 depression and, 401
 eating disorders and, 409–10
 plans, 105
 resistant hypertension, 444
 resolution, 263–4
 respiratory tract infections, 27
 retained tampons, 250
 reversible contraception, 19–23
 Rh immunoprophylaxes, 134
 right hypochondriac pain, 436
 right iliac pain, 436
 Ringer's lactate, 97–8
Roe v. Wade, 139
 ROS. *See* reactive oxygen species
 RPR. *See* rapid plasma reagin
 Rubella, 113
 ruptured ectopic pregnancy, 126
 rusty pipe syndrome, 33
 SAB. *See* spontaneous abortion
 safe driving practice, 11
 saline infusion sonohysteroscopy (SIS),
 51–2
 salpingitis, 186
 salpingostomy, 126
 sample medication algorithm, 73
 school, 34
 SCOFF questionnaire, 410
 second trimester, 133

Index

- secondary syphilis, 188
 sedation, 147
 seizures
 causes, 95–6
 initial management, 95–6
 investigations, 96
 office emergencies, 95
 pharmacologic therapy, 95–6
 selective estrogen receptor modulators, 474
 selective progesterone receptor modulators (SPRM), 259
 sexual dysfunction and, 268
 selective serotonin reuptake inhibitors (SSRIs), 111, 344, 389
 for depression, 399
 dosing, 399
 for PMS/PMDD, 390
 side effects, 390
 for UI, 230
 self-help materials, 427
 semen analysis, 286
 in infertility, 287–8
 septate uterus, 51, 361
 serotonin, 331, 389
 serotonin norepinephrine reuptake inhibitors (SNRIs)
 for depression, 399
 dosing, 399
 serous cystadenoma, 58, 216–17
 Sertoli-Leydig cell tumors, 327
 sertraline, 30
 sex cord-stromal tumors, 220
 sex hormone binding globulin (SHBG), 312
 sexual assault, 526
 approach to, 526–7
 assessment, 527
 follow-up, 530
 laboratory analysis, 529
 legal issues, 530–1
 long-term consequences of, 531
 patient education, 527
 physical exam, 527
 prevention, 531–2
 scope of problem, 526
 screening, 531
 society and, 532
 treatment, 529–30
 sexual desire/interest disorder, 264
 sexual dysfunction
 abuse and, 269
 age and, 268
 ALLOW model, 266–7
 anxiety and, 268
 approach to patient, 266–7
 bimanual exam, 269
 causes, 264–5
 combined sexual arousal disorder, 264
 comorbid conditions, 268
 contraception and, 268–9
 definition, 263
 depression and, 268
 detailed questionnaires, 269
 disability and, 513
 environment in, 266
 genital arousal disorder, 264
 of geriatric population, 502–3
 intimate partner violence and, 269
 medications and, 268
 mono-manual exam for, 269–70
 orgasmic disorder, 264, 271
 patient perception, 267
 persistent sexual arousal disorder, 264
 physical exam, 269–70
 PLISSIT model, 266–7
 POP and, 236
 pregnancy and, 268–9
 psychology and, 267
 risk factors, 265
 scope of, 265–6
 screening questionnaire, 266
 sexual desire/interest disorder, 264
 sexual history in, 267
 sexual pain, 271
 smoking and, 268
 social history and, 268
 speculum exam for, 269
 SSRIs and, 268
 subjective sexual arousal disorder, 264
 surgical history and, 269
 treatment, 270
 vaginismus, 264
 sexual history
 acute pelvic pain and, 199
 in sexual dysfunction, 267
 UI and, 223
 Sexual Interest and Desire Inventory – Female (SIDI-F), 269
 sexual pain, 271
 sexuality, disability and, 513
 sexually transmitted infections (STI), 184
 contraception and, 18
 screening, 489
 substance abuse disorders and, 489
 shadowing, 57
 shave biopsy, 77
 SHBG. *See* sex hormone binding globulin
 Sheehan's syndrome
 diagnosis, 352–3
 pathophysiology, 352
 symptoms, 352
 sickle cell disease, 109–10, 113
 SIDI-F. *See* Sexual Interest and Desire Inventory – Female
 SIGECAPS, 397
 Sim's speculum, 224
 SIS. *See* saline infusion sonohysteroscopy
 skeletal/gait issues, 236
 skin cancer screening, 500
 smoking
 annual examination, 11
 breastfeeding and, 30
 cessation, 12
 acupuncture and, 427
 antidepressants and, 427–9
 anxiolytics and, 427–9
 aversion therapy, 429
 barriers to, 429
 electronic cigarettes for, 429
 exercise and, 427
 financial issues, 429
 5 A's, 425
 group support, 427
 hypnotherapy and, 427
 motivational interviewing, 425–6
 nicotine replacement, 427, 428
 nonpharmacologic tools, 426–7
 pregnancy and, 430
 self-help materials, 427
 social history and, 429–30
 tools, 426
 trans-theoretical model of change, 424–5
 varenicline, 427
 weight gain and, 429
 deaths from, 424
 health costs associated with, 424
 osteoporosis and, 476
 outpatient infertility management, 298
 preconception counseling, 111
 prevalence of, 424
 reduction of, 426
 sexual dysfunction and, 268
 subfertility and, 286
 SNRIs. *See* serotonin norepinephrine reuptake inhibitors
 social history
 depression and, 395
 sexual dysfunction and, 268
 smoking cessation and, 429–30
 social support, 29–30
 sodium, 475–6
 solid organ transplant, 354
 somatotroph, 161
 somite stage, 53
 sonohysteroscopy, 50
 in uterine leiomyoma, 258
 space occupying pessary, 239

- speculum exam
 for sexual dysfunction, 269
 in subfertility, 286
 spironolactone, 318, 328
 spontaneous abortion (SAB), 118
 spontaneous preterm delivery (SPTD),
 prenatal care and, 130
 SPRM. *See* selective progesterone
 receptor modulators
 SPTD. *See* spontaneous preterm
 delivery
 squamous cell hyperplasia, 244
 SRY gene, 360–1
 SSRIs. *See* selective serotonin reuptake
 inhibitors
 St. John's Wort, 392
 Stages of Reproductive Aging
 Workshop, 341–2
 statins, 462
 sterilization
 disability and, 514
 hysteroscopic, 23–4
 laparoscopic, 23
 STI. *See* sexually transmitted infections
 STIK11, 45
 stimulant abuse
 behavioral therapy for, 488
 epidemiology, 488
 intoxication, 488
 withdrawal, 488
Streptococcus pyogenes, 157
 stress, 344
 stress incontinence, 221
 stroke prevention, 7–8
 Struma Ovarii, 351
 subchorionic bleeds, 54
 subclinical hyperthyroidism, 351
 subfertility, 285. *See also* infertility
 alcohol and, 286
 congenital anomalies, 286
 fertility scan, 288
 endometrium, 289–91
 hysteroscopy, outpatient, 293–4
 ovarian reserve assessment, 291–2
 tubal patency assessment, 292–3
 uterus, 289
 hormonal profile of female patients,
 287
 medical history in, 285–6
 outpatient evaluation, 285
 PCOS and, 292
 physical examination, 286
 smoking and, 286
 speculum exam in, 286
 ultrasound scan, 288
 subjective sexual arousal
 disorder, 264
 submucosal fibroids, 51
 submucosal leiomyoma, 256–7
 subserosal leiomyoma, 256–7
 substance use disorders (SUD), 487.
 See also specific substances
 in adolescents, 489
 annual exam, 11
 cervical cancer and, 489–90
 contraception and, 489
 ethical issues, 491
 legal issues, 491
 mental illness and, 483
 STIs and, 489
 vaccinations and, 490
 SUD. *See* substance use disorders
 sudden infant death syndrome, 27
 suicide, 394
 depression and, 395
 superficial dyspareunia, 204, 207–8
 supplements
 folic acid, 110–11
 herbal, 110–11
 preconception counseling, 110–11
 support pessaries, 238–9
 supraglottic device, 91
 surgical abortion
 antibiotic management, 147–8
 appropriate office candidate, 144
 cannula in, 144
 cervical lacerations and, 146
 cervical preparation, 144
 complications, 145–6
 dilators in, 144
 equipment, 144
 first trimester, 144
 general anesthesia, 147
 hematometra and, 146
 hemorrhage, 146
 incomplete, 146
 medical abortion and, 141
 pain management, 147
 paracervical block, 147
 premedications, 147
 procedure, 144–5
 sedation, 147
 uterine perforation in, 146
 vasovagal episodes, 146
 surgical approach, 64
 surgical history, 269
 surgical site infection prophylaxis,
 68–9
 symptomatic early pregnancy, 125
 syphilis
 pathophysiology, 188–9
 prenatal care, 132, 134–5
 primary, 188
 risks, 188
 screening, 10, 189
 secondary, 188
 tertiary, 188–9
 testing, 189
 treatment, 189–90
 Tuskegee syphilis experiment, 535
 systemic lupus erythematosus, 454
 preconception counseling, 107
 tachypnea, 98–9
 tamoxifen, 42, 377
 complications, 299
 mechanism of action, 299
 plan of treatment, 299
 tandem breastfeeding, 34
 Tay Sachs, 113
 TCAs. *See* tricyclic antidepressants
 TCRE. *See* transcervical resection of
 endometrium
 Td/Tdap. *See* tetanus, diphtheria, and
 pertussis immunization
 Teen Pregnancy Prevention Initiative,
 158
 telecommunications devices, 512
 telmisartan, 448–9
 tenofovir, 530
 teratospermia, 287
 terconazole, 246–8
 teriparatide, 474
 tertiary syphilis, 188–9
 testosterone, 270, 271, 322
 tetanus, diphtheria, and pertussis (Td/
 Tdap) immunization, 8, 497
 THC, 488–9
 third trimester, 134–6
 threatened abortion, 120–1
 thromboembolic disease, 109
 thrombophilia, 113
 thyroid disease, 12, 172, 349
 preconception counseling, 107–8
 thyroid stimulating hormone
 (TSH), 349
 screening with, 349–50
 transient elevation, 350
 thyroid storm, 350–1
 thyroid-releasing hormone (TRH), 331
 thyrotroph, 161
 thyroxine, 349
 timed voiding, 228
 tinidazole, 193
 tioconazole, 246–8
 Tischler forceps, 243
 TNF. *See* tumor necrosis factor alpha
 tobacco. *See* smoking
 toileting aids, 229
 topical steroids, 251
 topiramate, 485
 total incontinence, 222
 toxic goiter, 351
 toxoplasmosis, 111–12
 trandolapril, 448–9
 tranexademic acid, 259–60
 transcervical resection of endome-
 trium (TCRE), 100
 transdermal patch, 20
 transexamic acid, 157, 177

Index

- transient incontinence, 222
 trans-theoretical model of change, 424–5
 transvaginal ultrasound, 173
 for pelvic masses, 212
 transverse vaginal septum, 363
Treponema pallidum, 132
 TRH. *See* thyroid-releasing hormone
 trichloroacetic acid, 192
 trichomonas
 epidemiology, 192–3
 pathophysiology, 193
 screening, 193
 testing, 193
 treatment, 193
 trichomoniasis, 249–50
 diagnosis of, 249
 symptoms, 249
 tricyclic antidepressants (TCAs), 399–400
 triiodothyronine, 349
 trimethoprim-sulfamethoxazole, 384, 385
 TSH. *See* thyroid stimulating hormone
 tubal patency assessment, 292–3
 tuberculosis
 risk factors, 11
 screening, 10–11
 tubo-ovarian abscess, 214–15
 tumor necrosis factor alpha (TNF), 437
 Turner syndrome, 152–3, 364
 amenorrhea and, 162
 Tuskegee syphilis experiment, 535
 twins, 34
 type 2 diabetes mellitus, 27
 Tyrer model, 40
 UAE. *See* uterine artery embolization
 UC. *See* ulcerative colitis
 UI. *See* urinary incontinence
 ulcerative colitis (UC), 436–7
 ulipristal acetate, 259
 ultrasound, 49
 acute pelvic pain, 200
 amenorrhea, 166
 for aneuploidy, 133–4
 blighted ovum, 121
 breast complaints and, 369–70
 endometriosis, 277–8
 equipment selection, 49
 fertility scan, 288
 first trimester, 50
 first trimester, abnormal, 119–20
 infertility and, 58–9
 IUD placement, 78–9
 molar pregnancy, 123
 office procedure, 78–9
 in PCOS, 314, 317
 pelvic, 163
 indications for, 50
 pelvic masses, 212–13
 pelvic organ scanning, 51–2
 performance of, 50–1
 pregnancy and, 50, 52–4
 sonohysterography, 50
 subfertility, 288
 training, 49
 transvaginal, 173
 for pelvic masses, 212
 uterine leiomyoma, 258
 uterus
 congenital abnormalities in, 51
 pathology, 51–2
 utilization, 78–9
 unicornuate uterus, 361
 unintended pregnancy, 139
 adverse health events, 106
 continuation of, 139
 contraception counseling and, 148
 ureaplasma, 286
 urge incontinence, 221
 urinalysis, 207, 382
 in UI, 225
 urinary incontinence (UI), 221
 abdominal examination in, 224
 absorbent products, 229
 adrenoreceptor agonists, 230
 alternative management, 229
 antidepressants for, 230
 antimuscarinics for, 230–1
 behavioural therapies for, 228
 beta-3-adrenoceptor agonist
 for, 231
 biofeedback for, 227
 bladder diary, 225
 bladder training, 228
 bowel symptoms, 223
 catheters for, 229
 complementary therapies, 229–30
 conservative management, 226
 electrical stimulation, 228
 estrogens for, 230
 evaluation of, 222
 examination, 223
 flavoxate for, 226–31
 functional, 221–2
 assessment, 223
 in geriatric population, 502
 leakage prevention products, 229
 lifestyle modifications for, 226–7
 lower tract symptoms, 223
 magnetic therapy, 228
 mixed, 221
 neurological assessment, 225
 neurostimulation for, 228–9
 noradrenaline for, 230
 overflow, 221
 PAD test, 226
 patient history, 222–3
 PFME for, 227
 physical therapy for, 227
 post micturition, 223
 prompted voiding and, 228
 PVR in, 225–6
 QoL, 225
 rectal examination in, 224–5
 risk factors, 221
 sexual history, 223
 SSRIs for, 230
 stress, 221
 timed voiding for, 228
 toileting aids for, 229
 total, 222
 transient, 222
 treatment, 226
 types of, 221–2
 urge, 221
 urinalysis in, 225
 urodynamic study in, 226
 vaginal cones for, 227
 vaginal examination, 224
 voiding symptoms, 223
 urinary tract infection (UTI), 380
 antibiotics for, 384
 common pathogens, 383
 definition, 380
 diabetes mellitus and, 385–6
 epidemiology, 381
 history, 381–2
 indwelling catheters and, 386
 laboratory analysis in, 382
 microbiology, 382–3
 pathophysiology, 380–1
 physical exam, 382
 postmenopausal, 385
 pregnancy and, 385
 prevention, 384–5
 radiology, 382–3
 risk factors, 381
 scope of problems, 380
 treatment, 383
 urodynamic study, 226
 uterine artery embolization (UAE), 179, 260
 abnormal artery embolization, 179–81
 post embolization, 180
 uterine aspirate, 145
 uterine cavity, 121
 uterine fibroids, 180
 uterine leiomyoma. *See also* fibroids
 abdominal pain, 440
 CT in, 258
 differential diagnosis, 258
 genetics, 256
 menorrhagia in, 257
 pelvic pressure in, 257
 physical exam in, 257–8
 prevention, 260
 scope of, 255–6

- sonohysterography in, 258
- submucosal, 256–7
- subserosal, 256–7
- symptoms, 257
- treatment, 257, 259–60
- ultrasound, 258
- work up, 258
- uterine malposition, 124
- uterine myomas, 215
- uterine perforation, 146
- uterine sarcoma, 179
- uterine tract disorders, 162–3
- uterus. *See also* abnormal uterine bleeding
 - arcuate, 51, 361
 - bicornate, 51, 361
 - didelphys, 51, 361
 - fertility scan, 289
 - septate, 51, 361
 - transplantation, 362
 - ultrasound
 - congenital abnormalities in, 51
 - pathology, 51–2
 - unicornuate, 361
- UTI. *See* urinary tract infection
- vaccinations
 - preconception counseling, 113
 - substance abuse disorders and, 490
- vaginal atrophy, 345
- vaginal bleeding, 501–2
- vaginal cones, 227
- vaginal cysts, 246
- vaginal dilators, 362
- vaginal discharge, 250, 270
- vaginal disorders, 246–50
- vaginal examination, 224
- vaginal infections, 246
- vaginismus, 264
- vaginitis, yeast, 246–7
 - diagnosis, 246
- vaginoscopy, 294
- valacyclovir, 188
- Valsalva maneuver, 63
- valsartan, 448–9
- varenicline, 111, 428
 - smoking cessation, 427
- varicella, 113
 - immunizations, 8
- vasomotor symptoms
 - estrogen for, 344
 - menopause, 343–4
- vasovagal episodes, 146
- vasovagal reactions
 - immediate management, 100
 - office emergencies, 100
 - presentation, 100
- VDRL. *See* Venereal Disease Research Laboratories
- Vecchietti procedure, 362
- vegan diet, 110
- Venereal Disease Research Laboratories (VDRL), 132
- venous thromboembolism (VTE), 420
- venous thromboprophylaxis, 69
- verapamil, 448–9
- vertebral fractures, 468
- vestibulodynia, 271
- VIN. *See* vulvar intraepithelial neoplasia
- virilization, 322
 - at puberty, 357–8
- visual acuity, 497–8
- vitamin B6, 391–2
- vitamin B12, 110
 - sufficient intake, 113
- vitamin D, 391–2
 - insufficiency, 444
 - osteoporosis and, 475
 - recommendations, 4
- voiding symptoms, 223
- vomiting, 27
- Von Willebrand disease, 152–3
- VTE. *See* venous thromboembolism
- vulvar atrophy, 345
- vulvar biopsy, 77
- vulvar cysts, 243
- vulvar dermatoses, 244
- vulvar disorders, 243–6
- vulvar dysplasia, 245–6
- vulvar infections, 244
- vulvar intraepithelial neoplasia (VIN), 245
 - treatment, 246
- vulvar ulcers, 243–4
- vulvar vestibulitis syndrome (VVS), 207
- vulvitis, 501
- vulvovaginal candidiasis, 247–8
 - treatment, 246–7
 - uncomplicated, 246–7
- vulvovaginal infections, 246–8
- vulvovaginitis
 - differential diagnosis, 243
 - laboratory analysis, 155–6, 242–3
 - in PAG, 151, 153
 - patient history, 153, 242
 - physical exam, 154, 242
 - scope of, 242
 - treatment, 157
- VVS. *See* vulvar vestibulitis syndrome
- water intoxication syndrome
 - initial management, 101
 - investigations, 101
 - office emergencies, 100–1
 - presentation, 101
- weight
 - gain, 429
 - reduction, 297
- WHI. *See* Women's Health Initiative
- white-coat hypertension, 444
- Wolffian ducts, 360–1
- Women's Health Initiative (WHI), 346
- work, 34
- X chromosome, 162
- xylocaine, 77
- yeast vaginitis, 246–7
 - diagnosis, 246
- Yellow Fever, 30